

## Periodical Material in German

- Simon Klopschinski, *Arzneimittelrechtliche Genehmigungsverfahren, staatliche Preisfestsetzung und Kostenerstattung für Arzneimittel im Lichte des Patentschutzes – Rechtsprechungsübersicht Belgien, Deutschland, Frankreich und Österreich*, GRURInt. 993, (2011).
- Johanna Müller-Graff, Filipe Fischmann, *Der Fall AstraZeneca: “Tool boxes“ im Arzneimittelsektor – wer hat die besseren Werkzeuge und welche sind erlaubt? Zum Urteil des Gerichts der Europäischen Union vom 1. Juli 2010, Rs. T-321/05*, 792 GRUR Int 1, (2010).

## Non Periodical Material

- John E. Calfee, White Paper on Pharmaceutical Market Competition Issues, June 2, 2008, available at <http://62.102.106.100/content/default.asp?PageID=559&DocID=4894>.
- R. Thomas, *Patent “Evergreening”*: Issues in Innovation and Competition, Congressional Research Service, (Nov. 13, 2009).
- OECD Policy Roundtables, “Roundtable on Generic Pharmaceuticals 2009” DAF/COMP(2009) 39, Oct. 5, 2010 at 148.
- William C. Stewart, *Combination Therapy: Is the Whole Greater?*, Rev. Ophthalmol., Jun. 15, 2005.

## Table of books

- V. N. Bhat, *The Challenges of the new EU Pharmaceutical legislation Pharmaceuticals Policy and Law*, (1<sup>st</sup> ed. 2005).
- Kim B. Clark, Steven C. Wheelwright, *Managing New Product and Process Development: Text and Cases*, (1<sup>st</sup> ed. 1993).
- Bengt Domeij, *Pharmaceutical Patents in Europe*, (1<sup>st</sup> ed. 2000).
- Jan I. Drayer, James P. Burns, *From Discovery to Market: The Development of Pharmaceuticals*, in BURGER’S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, (1995).
- Philip W. Grubb, *Patents for Chemicals, Pharmaceuticals and Biotechnology* (5<sup>th</sup> ed. 2010).
- Sajiv K. Nair, Kevin E. Henegar, *Modern Drug Synthesis*, (1<sup>st</sup> ed. 2010).
- Kristof Roox, Julia Pike, Andrew Brown, Stefan Becker, *Patent-related Barriers to Market Entry for Generic Medicines in the European Union*, (2008).
- Ulrich Storz, *Biopatent Law: Patent Strategies and Patent Management*, (1<sup>st</sup> ed. 2012).
- Derk Visser, *The annotated European patent convention*, (17th ed., 2009).

## Table of Cases

### European Union

- ECJ, C-322/10, *Medeva BV v. Comptroller General of Patents, Designs and Trade Marks*, November 24, 2011.
- ECJ, C-422/10, *Georgetown University, University of Rochester, Loyola University of Chicago v. Comptroller General of Patents, Designs and Trade Marks*, November 24, 2011.
- European General Court, T-321/05, *AstraZeneca v Commission*, July 1, 2010, E.C.R. II-02805.

### EPO Board of Appeal

- G 5/83, Official Journal EPO, 64, 1985.
- T 307/03 Official Journal (OJ), 418, 2009.
- T 1423/07, EPO Board of Appeal decisions database available at <http://www.epo.org/law-practice/case-law-appeals/recent/t071423eu1.html>.

### France

- Aventis v. Teva*: Tribunal de Grande Instance de Paris, Mar. 17 2011, available at [http://kluwerpatentblog.com/files/2010/12/2010-08-19\\_TGI\\_Paris\\_Aventis\\_Teva\\_translation.pdf](http://kluwerpatentblog.com/files/2010/12/2010-08-19_TGI_Paris_Aventis_Teva_translation.pdf).

### Germany

- BundesPatentGericht (BPatG) [Federal Patent Court] June 15, 2010, BeckRS, 24071, 2010 (Ger.).
- BundesPatentGericht (BPatG) [Federal Patent Court] Mar. 1, 2011, BeckRS, 14402, 2011 (Ger.).
- Landgericht Düsseldorf [Regional Court] Feb. 24, 2004, GRUR, 193, 2004 (Ger.).

### Italy

- Autorità Garante della Concorrenza e del Mercato [Competition Authority], Jan. 30, 2012 Bollettino 5 (XXII-2) (It.).